F. G. Demirkan Et Al. , "Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group," EXPERT OPINION ON BIOLOGICAL THERAPY , vol.22, no.2, pp.197-202, 2022
Demirkan, F. G. Et Al. 2022. Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group. EXPERT OPINION ON BIOLOGICAL THERAPY , vol.22, no.2 , 197-202.
Demirkan, F. G., Ulu, K., Ozturk, K., Karadas, S. G., Ozdel, S., SÖNMEZ, H. E., ... Cakmak, F.(2022). Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group. EXPERT OPINION ON BIOLOGICAL THERAPY , vol.22, no.2, 197-202.
Demirkan, Fatma Et Al. "Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group," EXPERT OPINION ON BIOLOGICAL THERAPY , vol.22, no.2, 197-202, 2022
Demirkan, Fatma G. Et Al. "Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group." EXPERT OPINION ON BIOLOGICAL THERAPY , vol.22, no.2, pp.197-202, 2022
Demirkan, F. G. Et Al. (2022) . "Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group." EXPERT OPINION ON BIOLOGICAL THERAPY , vol.22, no.2, pp.197-202.
@article{article, author={Fatma Gul Demirkan Et Al. }, title={Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group}, journal={EXPERT OPINION ON BIOLOGICAL THERAPY}, year=2022, pages={197-202} }